PTC
VRTX icon

Philadelphia Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Philadelphia Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,985
Closed -$5.93M – 260
2021
Q4 		$5.93M Buy
26,985
+25,100
+1,332% +$4.88M 0.43% 52
2021
Q3 		$342K Sell
1,885
-18,810
-91% -$3.67M 0.03% 195
2021
Q2 		$4.17M Buy
+20,695
New +$4.33M 0.29% 71
2021
Q1 		– Sell
-6,930
Closed -$1.64M – 226
2020
Q4 		$1.64M Buy
+6,930
New +$1.59M 0.13% 98

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Philadelphia Trust Company's VRTX Position: Q1 2022 in Review

Philadelphia Trust Company sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 26,985 shares — an estimated $5.93M sold.

Philadelphia Trust Company first reported a position in VRTX in Q4 2020 and held it in 4 quarters. The position peaked at $5.93M in Q4 2021. 1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • Philadelphia Trust Company reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Philadelphia Trust Company sold 26,985 Vertex Pharmaceuticals shares in Q1 2022, an estimated $5.93M.
  • Philadelphia Trust Company first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Philadelphia Trust Company's Vertex Pharmaceuticals position peaked at $5.93M in Q4 2021.
  • 1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Philadelphia Trust Company's 13F filing for Q1 2022, filed 5 May 2022.